Matrix metalloproteinases 2 and 9 and MMP9/NGAL complex activity in women with PCOS

Reproduction

Volumn 151, Issue 4, 2016, Pages 305-311

  Ranjbaran, Javad ^a   Farimani, Marzieh ^b   Tavilani, Heidar ^a   Ghorbani, Marzieh ^b   Karimi, Jamshid ^a   Poormonsefi, Faranak ^b   Khodadadi, Iraj ^a  

^a HAMADAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b SEMNAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; ESTRADIOL; FOLLITROPIN; GELATINASE A; GELATINASE B; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LUTEINIZING HORMONE; MATRIX METALLOPROTEINASE 9 NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN COMPLEX; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; SEX HORMONE BINDING GLOBULIN; TESTOSTERONE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; LCN2 PROTEIN, HUMAN; MMP2 PROTEIN, HUMAN; MMP9 PROTEIN, HUMAN; TIMP1 PROTEIN, HUMAN;

ADULT; ARTICLE; BODY MASS; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; ESTRADIOL BLOOD LEVEL; FEMALE; FOLLITROPIN BLOOD LEVEL; GLUCOSE BLOOD LEVEL; GROUPS BY AGE; HUMAN; INSULIN BLOOD LEVEL; LUTEINIZING HORMONE BLOOD LEVEL; OVARY POLYCYSTIC DISEASE; PRIORITY JOURNAL; TESTOSTERONE BLOOD LEVEL; TRIACYLGLYCEROL BLOOD LEVEL; CASE CONTROL STUDY; COMPARATIVE STUDY; METABOLISM; OVARY; PATHOLOGY;

BIOMARKERS; CASE-CONTROL STUDIES; FEMALE; HUMANS; LIPOCALIN-2; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; OVARY; POLYCYSTIC OVARY SYNDROME; TISSUE INHIBITOR OF METALLOPROTEINASE-1;

EID: 84962566824     PISSN: 14701626     EISSN: 17417899     Source Type: Journal    
DOI: 10.1530/REP-15-0340     Document Type: Article

References (34)

1. Amalinei C, Caruntu ID, Giusca SE & Balan RA 2010 Matrix metalloproteinases involvement in pathologic conditions. Romanian Journal of Morphology and Embryology 51 215-228.
2. Baka S, Zourla K, Kouskouni E, Makrakis E, Demeridou S, Tzanakaki D, Hassiakos D & Creatsas G 2000 Matrix metalloproteinases 2 and 9 and their tissue inhibitors in the follicular fluid of patients with polycystic ovaries undergoing in vitro fertilisation. In Vivo 24 293-296.
3. Bolignano D, Donato V, Lacquaniti A, Fazio MR, Bono C, Coppolino G & Buemi M 2010 Neutrophil gelatinase-associated lipocalin (NGAL) in human neoplasias: a new protein enters the scene. Cancer Letters 288 10-16. (doi:10.1016/j.canlet.2009.05.027)
4. Bouchet S & Bauvois B 2014 Neutrophil gelatinase-associated lipocalin (NGAL), pro-matrix metalloproteinase-9 (pro-MMP-9) and their complex pro-MMP-9/NGAL in leukaemias. Cancers 6 796-812. (doi:10.3390/cancers6020796)
5. Cakal E, Ozkaya M, Engin-Ustun Y & Ustun Y 2011 Serum lipocalin-2 as an insulin resistance marker in patients with polycystic ovary syndrome. Journal of Endocrinological Investigation 34 97-100. (doi:10.1007/BF03347037)
6. Diamanti-Kandarakis E, Livadas S, Kandarakis SA, Margeli A & Papassotiriou I 2008 Serum concentrations of atherogenic proteins neutrophil gelatinase-associated lipocalin and its complex with matrix metalloproteinase-9 are significantly lower in women with polycystic ovary syndrome: hint of a protective mechanism? European Journal of Endocrinology 158 525-531. (doi:10.1530/EJE-07-0822)
7. Dumesic DA & Abbott DH 2008 Implications of polycystic ovary syndrome on oocyte development. Seminars in Reproductive Medicine 26 53-61. (doi:10.1055/s-2007-992925)
8. Dumesic DA, Padmanabhan V & Abbott DH 2008 Polycystic ovary syndrome and oocyte developmental competence. Obstetrical & Gynecological Survey 63 39-48. (doi:10.1097/OGX.0b013e31815e85fc)
9. Fanjul-Fernandez M, Folgueras AR, Cabrera S & Lopez-Otin C 2010 Matrix metalloproteinases: evolution, gene regulation and functional analysis in mouse models. Biochimca et Biophysica Acta 1803 3-19. (doi:10.1016/j.bbamcr.2009.07.004) (doi:10.1016/j.bbamcr.2009.07.004)
10. Friedewald WT, Levy RI & Fredrickson DS 1972 Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clinical Chemistry 18 499-502.
11. Gerlach RF, Uzuelli JA, Souza-Tarla CD & Tanus-Santos JE 2005 Effect of anticoagulants on the determination of plasma matrix metalloproteinase (MMP)-2 and MMP-9 activities. Analytical Biochemistry 344 147-149. (doi:10.1016/j.ab.2005.04.038)
12. Gerlach RF, Demacq C, Jung K & Tanus-Santos JE 2007 Rapid separation of serum does not avoid artificially higher matrix metalloproteinase (MMP) - 9 levels in serum versus plasma. Clinical Biochemistry 40 119-123. (doi:10.1016/j.clinbiochem.2006.10.007)
13. Gerlach RF, Meschiari CA, Marcaccini AM, Palei AC, Sandrim VC, Cavalli RC & Tanus-Santos JE 2009 Positive correlations between serum and plasma matrix metalloproteinase (MMP)-2 or MMP-9 levels in disease conditions. Clinical Chemistry and Laboratory Medicine 47 888-891. (doi:10.1515/CCLM.2009.203)
14. Goldman S & Shalev E 2004 MMPS and TIMPS in ovarian physiology and pathophysiology. Frontiers in Bioscience 9 2474-2483. (doi:10. 2741/1409)
15. Gomes VA, Vieira CS, Jacob-Ferreira AL, Belo VA, Soares GM, Fernandes JB, Ferriani RA & Tanus-Santos JE 2001 Imbalanced circulating matrix metalloproteinases in polycystic ovary syndrome. Molecular and Cellular Biochemistry 353 251-257. (doi:10.1007/s11010-011-0793-6)
16. Goncalves FM, Jacob-Ferreira AL, Gomes VA, Casella-Filho A, Chagas AC, Marcaccini AM, Gerlach RF & Tanus-Santos JE 2009 Increased circulating levels of matrix metalloproteinase (MMP)-8, MMP-9, and pro-inflammatory markers in patients with metabolic syndrome. Clinica Chimica Acta 403 173-177. (doi:10.1016/j.cca.2009.02.013)
17. Lahav-Baratz S, Kraiem Z, Shiloh H, Koifman M, Ishai D & Dirnfeld M 2003 Decreased expression of tissue inhibitor of matrix metalloproteinases in follicular fluid from women with polycystic ovaries compared with normally ovulating patients undergoing in vitro fertilization. Fertility and Sterility 79 567-571. (doi:10.1016/S0015-0282 (02) 04838-0)
18. Lewandowski KC, Komorowski J, O'Callaghan CJ, Tan BK, Chen J, Prelevic GM & Randeva HS 2006 Increased circulating levels of matrix metalloproteinase-2 and -9 in women with the polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism 91 1173-1177. (doi:10.1210/jc.2005-0648)
19. Liu B, Guan YM & Zheng JH 2007 Elevated serum levels of matrix metalloproteinase-2 in women with polycystic ovarian syndrome. International Journal of Gynaecology and Obstetrics 96 204-205. (doi:10.1016/j.ijgo.2006.11.012)
20. Liu B, Cai LY, Lv HM, Xia L, Zhang YJ, Zhang HX & Guan YM 2008 Raised serum levels of matrix metalloproteinase-9 in women with polycystic ovary syndrome and its association with insulin-like growth factor binding protein-1. Gynecological Endocrinology 25 285-288. (doi:10.1080/09513590802056995)
21. Livadas S, Kollias A, Panidis D & Diamanti-Kandarakis E 2014 Diverse impacts of aging on insulin resistance in lean and obese women with polycystic ovary syndrome: evidence from 1345 women with the syndrome. European Journal of Endocrinology 171 301-309. (doi:10.1530/EJE-13-1007)
22. Lujan ME, Chizen DR & Pierson RA 2008 Diagnostic criteria for polycystic ovary syndrome: pitfalls and controversies. Journal of Obstetrics and Gynaecology Canada 30 671-679.
23. Mason H, Colao A, Blume-Peytavi U, Rice S, Qureshi A, Pellatt L, Orio F & Atkin SL 2008 Polycystic ovary syndrome (PCOS) trilogy: a translational and clinical review. Clinical Endocrinology 69 831-844. (doi:10.1111/j.1365-2265.2008.03329.x)
24. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF & Turner RC 1985 Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28 412-419. (doi:10.1007/BF00280883)
25. Moran C, Arriaga M, Arechavaleta-Velasco F & Moran S 2015 Adrenal androgen excess and body mass index in polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism 100 942-950. (doi:10. 1210/jc.2014-2569)
26. Murphy G 2011 Tissue inhibitors of metalloproteinases. Genome Biology 12 233. (doi:10.1186/gb-2011-12-11-233)
27. Nagase H, Visse R & Murphy G 2006 Structure and function of matrix metalloproteinases and TIMPs. Cardiovascular Research 69 562-573. (doi:10.1016/j.cardiores.2005.12.002)
28. Panidis D, Tziomalos K, Koiou E, Kandaraki EA, Tsourdi E, Delkos D, Kalaitzakis E & Katsikis I 2000 The effects of obesity and polycystic ovary syndrome on serum lipocalin-2 levels: a cross-sectional study. Reproductive Biology and Endocrinology 8 1-8. (doi:10.1186/1477-7827-8-151)
29. Rosner W, Auchus RJ, Azziz R, Sluss PM & Raff H 2007 Position statement: utility, limitations, and pitfalls in measuring testosterone: an Endocrine Society position statement. Journal of Clinical Endocrinology and Metabolism 92 405-413. (doi:10.1210/jc.2006-1864)
30. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group 2004 Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertility and Sterility 81 19-25.
31. Sahin SB, Cure MC, Ugurlu Y, Ergul E, Gur EU, Alyildiz N & Bostan M 2014 Epicardial adipose tissue thickness and NGAL levels in women with polycystic ovary syndrome. Journal of Ovarian Research 7 1-6. (doi:10. 1186/1757-2215-7-24)
32. Shalev E, Goldman S & Ben Shlomo I 2001 The balance between MMP-9 and MMP-2 and their tissue inhibitor (TIMP)-1 in luteinized granulosa cells: comparison between women with PCOS and normal ovulatory women. Molecular Human Reproduction 7 325-331. (doi:10.1093/molehr/7.4.325)
33. Souza-Tarla CD, Uzuelli JA, Machado AA, Gerlach RF & Tanus-Santos JE 2005 Methodological issues affecting the determination of plasma matrix metalloproteinase (MMP)-2 and MMP-9 activities. Clinical Biochemistry 38 410-414. (doi:10.1016/j.clinbiochem.2005.02.010)
34. Tsai HC, Ye SY, Kunin CM, Lee SS, Wann SR, Tai MH, Shi MH, Liu YC & Chen YS 2011 Expression of matrix metalloproteinases and their tissue inhibitors in the serum and cerebrospinal fluid of patients with HIV-1 infection and syphilis or neurosyphilis. Cytokine 54 109-116. (doi:10.1016/j.cyto.2011.02.007)